1. Home
  2. UCAR vs GRDX Comparison

UCAR vs GRDX Comparison

Compare UCAR & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U Power Limited

UCAR

U Power Limited

SELL

Current Price

$3.00

Market Cap

6.9M

ML Signal

SELL

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

HOLD

Current Price

$3.17

Market Cap

33.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCAR
GRDX
Founded
2013
N/A
Country
China
United Kingdom
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
33.2M
IPO Year
2022
2016

Fundamental Metrics

Financial Performance
Metric
UCAR
GRDX
Price
$3.00
$3.17
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.5K
★ 147.2K
Earning Date
11-06-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.95
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.51
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.04
$1.87
52 Week High
$8.99
$6.93

Technical Indicators

Market Signals
Indicator
UCAR
GRDX
Relative Strength Index (RSI) 47.63 36.24
Support Level $1.02 $3.23
Resistance Level $3.29 $4.19
Average True Range (ATR) 0.40 0.79
MACD 0.02 -0.26
Stochastic Oscillator 58.52 26.36

Price Performance

Historical Comparison
UCAR
GRDX

About UCAR U Power Limited

U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: